Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells

Blood

Volumn 105, Issue 5, 2005, Pages 2016-2022

  Zeng, Yi ^a   Graner, Michael W ^a   Thompson, Sylvia ^a   Marron, Marilyn ^a   Katsanis, Emmanuel ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CHAPERONE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCYLPHENYLALANYLYSYLGLUTAMINYLSERYLSERYLLYSYLALANYLEUCINE; HEAT SHOCK PROTEIN; HYBRID PROTEIN; LEUCINE; PEPTIDE; UNCLASSIFIED DRUG; CANCER VACCINE; CELL EXTRACT; PEPTIDE FRAGMENT; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL LYSATE; CELL SURVIVAL; CHAPERONE RICH CELL LYSATE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR CELL; VACCINATION; ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CYTOLOGY; IMMUNOLOGY; LEUKEMIA; PATHOLOGY; PHYSIOLOGY; SECRETION; SPLEEN; TRANSPLANTATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CELL EXTRACTS; CELL LINE, TUMOR; DENDRITIC CELLS; FUSION PROTEINS, BCR-ABL; IMMUNITY; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LEUKEMIA; MICE; MICE, INBRED BALB C; MOLECULAR CHAPERONES; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; SPLEEN; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 14944386039     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-05-1915     Document Type: Article

References (52)

1. Graner M, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother. 2003;52:226-234.
2. Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood. 2003;101:4485-4491.
3. Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol Immuno-therapy. 2000;49:476-484.
4. + murine leukemia. Intl J Cancer. 2004;110:251-259.
5. Srivastava PK, Maki RG. Stress-induced proteins in immune response to cancer. Curr Top Microbiol Immunol. 1991;167:109-123.
6. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chap-eroning of the innate and adaptive immune responses. Ann Rev Immunol. 2002;20:395-425.
7. Reits E, Griekspoor A, Neijssen J, et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity. 2003;18:97-108.
8. Princiotta MF, Finzi D, Qian SB, et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity. 2003;18:343-354.
9. Baker-LePain JC, Sarzotti M, Fields TA, Li CY, Nicchitta CV. GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med. 2002;196:1447-1459.
10. Nicchitta CV. Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nat Rev Immunol. 2003;3:427-432.
11. Daley GQ. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
12. Matulonis UA. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Cancer Genet Cytogenet. 2001;126:8-12.
13. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41:178-228.
14. Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysates activate dendritic cells and elicit potent anti-tumor immunity. Blood. 2003;101:4485-4491.
15. Graner M. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res. 2000;6:909-915.
16. Fields RC, Osterholzer JJ, Fuller JA, Thomas EK, Geraghty PJ, Mule JJ. Comparative analysis of murine dendritic cells derived from spleen and bone marrow. J Immunother. 1998;21:323-339.
17. Rotzschke O, Falk K, Wallny HJ, Faath S, Rammensee HG. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science. 1990;249:283-287.
18. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351:290-296.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc. 1972;A135:185-207.
21. He L, Feng H, Raymond A, et al. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol Immunother. 2001;50:31-40.
22. Pinilla-lbarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95:1781-1787.
23. Cathcart K, Pinilla-lbarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myetoid leukemia. Blood. 2004;103:1037-1042.
24. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol. 2002;2:185-194.
25. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer. 2000;88:232-238.
26. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 1995;269:1585-1588.
27. Nieland TJ, Tan MC, Monne-van Muijen M, Koning F, Kruisbeek AM, van Bleek GM. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc Natl Acad Sci U S A. 1996;93:6135-6139.
28. Heikema A, Agsteribbe E, Wilschut J, Huckriede A. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenie peptides. Immunol Lett. 1997;57:69-74.
29. Meng SD, Gao T, Gao GF, Tien P. HBV-specific peptide associated with heat-shock protein gp96. Lancet. 2001;357:528-529.
30. Arnold D, Faath S, Rammensee H, Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med. 1995;182:885-889.
31. Breloer M, Marti T, Fleischer B, von Bonin A. Isolation of processed, H-2Kb-binding ovalbumin-derived peptides associated with the stress proteins HSP70 and gp96. Eur J Immunol. 1998;28:1016-1021.
32. Nair S, Wearsch PA, Mitchell DA, Wassenberg JJ, Gilboa E, Nicchitta CV. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J Immunol. 1999;162:6426-6432.
33. Inoue K, Sugiyama H. [WT 1 and leukemia]. Rinsho Ketsueki. 1995;36:552-558.
34. Nakao S. Identification of novel minor histocom-patibility antigens responsible for graft-versus-leukemia (GVL) effect on chronic myeloid leukemia: usefulness of determining the clonotype of T cells associated with GVL effect after donor leukocyte infusion. Int J Hematol. 2002;76(suppl 1):274-276.
35. van der Harst D, Goulmy E, Falkenburg JH, et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood. 1994;83:1060-1066.
36. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic pro teinase 3 peptide preferentially inhibit chrome myeloid leukemia colony-forming units. Blood. 1997;90:2529-2534.
37. Breloer M, Fleischer B, von Bonin A. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. J Immunol. 1999;162:3141-3147.
38. + T cell Th1 cytokine production in vivo. J Immunol. 2004;172:4195-4203.
39. Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem. 2001;276:17163-17171.
40. Menoret A, Peng P, Srivastava PK. Association of peptides with heat shock protein gp96 occurs in vivo and not after cell lysis. Biochem Biophys Res Commun. 1999;262:813-818.
41. Arnold-Schild D, Hanau D, Spehner D, et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 1999;162:3757-3760.
42. Ishii T, Udono H, Yamano T, et al. Isolation of MHC class l-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol. 1999;162:1303-1309.
43. Castellino F, Boucher PE, Eichelberg K, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med. 2000;191:1957-1964.
44. Singh-Jasuja H, Toes RE, Spee P, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med. 2000;191:1965-1974.
45. Clark RE. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 2001;98:2887-2893.
46. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 1995;85:2680-2684.
47. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T-cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 1998;101:2290-2296.
48. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 1996;88:3522-3527.
49. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-denved peptides. Blood. 1996;87:3587-3592.
50. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76-94.
51. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood. 2003;101:245-252.
52. Buteau C, Markovic SN, Cells E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clinic Proc. 2002;77:339-349.